Establishment of a human fusion partner for making human T-T hybridomas which can grow in serum free medium.
A new human fusion partner, ICLU-T was established for making human T-T hybridomas. Some 6-thioguanine resistant (6-TGr) clones were separated from human T cell acute lymphocytic leukemia, PEER. The fastest growing clone of the 6-TGr cells was scaled up and was cultured in serum free medium. The clone that proliferated most quickly in the serum free medium was separated and named ICLU-T. When ICLU-T was fused with human peripheral blood lymphocytes by using only polyethylene glycol, the viability of fused cells was below 20% just after fusion and the fusion efficiency was 0.01-0.02 per 10(5) parent cells. Whereas, the combined use of 1% lecithin with polyethylene glycol increased the viability over 50% and the fusion efficiencies over 0.2 per 10(5) parent cells on the average. In a total of 34 clones of obtained hybridomas, there were 25 CD2 positive clones. CD4 positive or CD8 positive clones of the CD2 positive clones were 12 and 5 clones, respectively. Further, 4 clones of all hybridomas were CD19 positive, and one clone of these hybridomas was an Ig producer. These obtained hybridomas could proliferate in serum free medium.
Kawahara
H
H
National Research Institute of Vegetables, Ornamental Plants and Tea, Shizuoka, Japan.
Maeda-Yamamoto
M
M
Hakamata
K
K
D002455:Cell Division; D002459:Cell Fusion; D002460:Cell Line; D016895:Culture Media, Serum-Free; D006801:Humans; D006825:Hybridomas / Q000502:physiology*; D010713:Phosphatidylcholines / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000494:pharmacology; D013601:T-Lymphocytes / Q000502:physiology*
D016895:Culture Media, Serum-Free; D010713:Phosphatidylcholines; D011092:Polyethylene Glycols